Solution Selling
Pain-driven, customer-centric, broadly applicable. PPVVC — Pain, Power, Vision, Value, Consensus — is the diagnostic core. Free scorecard, free AI practice.
Free to start. No credit card.
[CUSTOMER OUTCOME TO SOURCE: Solution Selling adoption / discovery quality outcome]
What is Solution Selling?
Solution Selling is a customer-centric, pain-driven B2B sales methodology that emphasises diagnosis over pitching. The seller acts as a consultant: diagnose Pain, identify Power, help the buyer articulate Vision, co-quantify Value, and build Consensus across the buying group. The diagnostic core is PPVVC.
The methodology was developed by Michael Bosworth in the 1980s and formalised through Sales Performance International (SPI). It is one of the earliest formal consultative-sales methodologies — SPIN Selling, Challenger, and MEDDIC all trace lineage through the pain-diagnosis model Bosworth popularised. Broadly applicable across complex B2B, and particularly strong where the buyer needs help defining what \"solved\" looks like before they can decide.
Solution Selling pairs cleanly with qualification frameworks. MEDDIC and MEDDPICC gate the funnel — is this deal real, is the Economic Buyer engaged, is the Decision Process mapped. Solution Selling drives what happens inside each qualified deal — how discovery actually gets done, how Vision gets built, how Value gets co-quantified, how Consensus gets stitched together across a modern multi-stakeholder buying group.
PPVVC component by component
Each component is a discovery gate. Below: what it means, a concrete example, and the most common way reps get it wrong.
Pain
The defined business issue creating urgency. No acknowledged pain, no decision. Solution Selling starts here — until the buyer names the pain in their own language, everything downstream is a sales rep pitching to an audience.
"Our reps ramp too slowly — median time-to-first-quota is 9 months, target is 4, and every quarter we miss it costs the CRO the plan. My VP of Sales flagged it as a top-three priority in the QBR." Named, quantified, owned by a stakeholder with authority to act.
Reps pitch product before Pain is acknowledged. The buyer nods politely at the demo, and the deal quietly dies because the pain was assumed — not surfaced. Solution Selling's whole edge collapses when this letter is skipped.
Power
The decision-makers identified and engaged. Maps to MEDDIC's Economic Buyer but Solution Selling frames it around influence and consensus, not just budget authority. Selling into a Coach who lacks Power is the fastest way to a stalled deal.
The VP of Sales owns the ramp-time metric and controls the enablement budget; the CRO signs anything above $100K; the RevOps lead is the technical decision-maker on the tooling review. Priya (rep) has met all three by week 3.
Reps confirm the enthusiastic user as Power and skip the executive meeting. In week 9 the actual decision-maker sees the proposal for the first time and has different priorities. Missing Power early is the most expensive Solution Selling mistake.
Vision
The buyer articulates what a successful solution looks like — in their terms, not the seller's. Not "our product does X," but "we would know it worked when new reps close their first opportunity by week 8 and hit quota by month 5." Vision the buyer owns is Vision the buyer will fight for.
Priya asks: "What would need to be true in six months for you to look back and say the programme worked?" The VP describes new hires certifying against MEDDIC by week 6, running independent first-meetings by week 8, and a manager dashboard she can pull up in her Monday 1:1 with the CRO.
Seller frames the Vision and the buyer nods along. The buyer doesn't own the outcome — so when procurement pushes back, the buyer has no personal narrative to defend the purchase with.
Value
The measurable benefit tied to solving the problem — the bridge from Pain to budget. Co-quantified with the buyer, not seller-asserted. Value the buyer contributed to the number is Value the buyer will defend at the budget conversation.
Together: "Cutting ramp from 9 months to 4 saves ~$180K per new hire in lost opportunity cost; the team hires 12 reps next year; that's $2.16M — and the CRO's Q4 plan currently has a hole of that size." The buyer did the arithmetic; the seller helped structure it.
Seller hands over a case-study stat and moves on. The buyer nods, doesn't internalise the number, and the ROI conversation collapses when the CFO asks a follow-up the seller can't answer without the buyer's data.
Consensus
Agreement across the buying group. Modern B2B rarely has one decision-maker — the average deal has 6+ stakeholders and any of them can veto. Without Consensus, deals slip even after the Economic Buyer says yes.
Priya has mapped: VP of Sales (Champion + Power), CRO (final sign-off), RevOps lead (technical veto risk), and the two front-line managers whose teams will actually use the system. She's run 1:1s with each; the RevOps lead's integration concern is addressed in week 5, not week 11.
Rep runs the deal through one enthusiastic buyer and misses the veto in another stakeholder. Deal closes on the Champion's yes, then unwinds three weeks later when the RevOps lead escalates a security concern that would have been trivial to address in discovery.
Need qualification rigour on top of discovery? Solution Selling's PPVVC pairs cleanly with MEDDIC's qualification gates. See MEDDIC →
Reading the components is not the same as running them. Practise PPVVC against an AI buyer with a Solution Selling scorecard.
Practise Solution Selling with AIWorked example: a consultative B2B deal, qualified with PPVVC
The deal. Acme, a Series-B SaaS company selling a sales-readiness product, has a $120K ARR opportunity at RampCo — a 1,500-employee professional services firm scaling its outbound sales motion. The rep, Priya, runs the deal through PPVVC across a ~90-day cycle. The alternatives the buyer is weighing are \"the status-quo\" (their current Google-Doc onboarding programme) and \"the build-in-house option\" (an internal-only LMS build the VP of Sales has floated). Priya's job is to help the buyer diagnose what solved looks like — not to argue against those alternatives.
Pain. Priya runs a discovery call with the VP of Sales in week 2. She doesn't pitch. She asks: \"When you look at the ramp cohort from last quarter, what specifically frustrates you?\" Fifteen minutes in, the VP has named the pain in her own language: median time-to-first-quota is 9 months, target is 4, every quarter the team misses it costs the CRO the plan, and the last QBR ended with the CRO flagging ramp as a top-three priority. Named, quantified, owned.
Power — the load-bearing letter. Priya confirms in week 3 that Power sits with the VP of Sales (owns ramp-time metric, controls enablement budget up to $150K), plus the CRO for anything above that. She asks for and gets a 25-minute meeting with the CRO in week 4. Most Solution Selling deals stall because the rep never gets here. Priya's didn't.
Vision. Rather than describing what Acme's product does, Priya asks the VP: \"What would need to be true in six months for you to look back and say the ramp programme worked?\" The VP describes new hires certifying against MEDDIC by week 6, running independent first-meetings by week 8, and a manager dashboard she can pull up in her Monday 1:1 with the CRO. The Vision is the VP's — in her language, with her measures. Priya writes it down verbatim.
Value. Together in week 5, Priya and the VP quantify: cutting ramp from 9 months to 4 saves ~$180K per new hire in lost opportunity cost; RampCo hires 12 reps next year; that's $2.16M — and the CRO's Q4 plan currently has a gap of that size. The VP did the arithmetic; Priya helped structure the math. When the CFO asks for the ROI model in week 8, the VP presents it as her own numbers — because they are.
Consensus. Priya has mapped the buying group by week 4: VP of Sales (Champion + Power), CRO (final sign-off), RevOps lead (technical veto risk on Salesforce integration), and the two front-line sales managers whose teams will actually run the programme. She runs a 20-minute 1:1 with the RevOps lead in week 5; his integration concern is that Acme's Salesforce sync is bi-directional, which resolves in one call. That concern would have derailed the deal in week 11 if it had surfaced then. It didn't, because Consensus was built in week 4, not deferred to week 10.
The two lessons. First, Vision was the VP's — not Priya's. That's what let the VP defend the purchase to the CFO in week 8 with personal conviction. Second, Consensus was built in discovery, not in pipeline recovery. The RevOps veto risk became a solved question in week 5 rather than a slipped deal in week 11.
Outcome. [CUSTOMER OUTCOME TO SOURCE: deal close timeline, first-year adoption metric, expansion outlook.]
Five common Solution Selling mistakes
Pitching before Pain is acknowledged
Solution Selling's edge is diagnosis. The moment the rep starts pitching capability before the buyer has named the pain, the framework collapses into vendor-selling. The pain has to be surfaced in the buyer's own language, at their initiative, with the seller's questions as the vehicle — not the seller's slides as the pitch. Reps who skip this letter turn Solution Selling into a wrapper over feature-selling and lose the differentiation entirely.
No Power identification (selling into a Coach)
An enthusiastic user is a Coach, not Power. Coaches provide information and rehearse messaging; Power signs contracts. Reps who mistake a Coach for Power skip the executive meeting and discover in week 9 that the actual decision-maker has different priorities. Power identification is a week-3 discipline, not a late-stage concern.
Vision in seller's terms, not buyer's
"You would know it worked when you deploy our platform and see the dashboard" is seller-framed Vision. "You would know it worked when new hires certify by week 6 and the CRO stops flagging ramp in the QBR" is buyer-framed Vision. The difference determines whether the buyer defends the purchase to procurement or shrugs when the CFO asks why now.
Value handed over late — after the buyer has already priced you
By the time the seller quantifies Value in week 7, the buyer has already ballparked the seller against alternatives at their asking price. Value that arrives after pricing is a defensive argument, not a differentiator. Value co-quantified in week 3 sets the frame; Value quantified in week 7 responds to it. The two conversations feel identical to the seller and land completely differently for the buyer.
No Consensus — deal slips after the EB says yes
Modern B2B deals rarely close on one signature — even after the Economic Buyer says yes, adjacent stakeholders can veto or slow-walk. [METRIC TO SOURCE: single-stakeholder vs multi-stakeholder close rates.] Consensus-building is week-3 discovery work, not week-11 pipeline recovery. Reps who defer Consensus until "the deal is close" spend Q3 explaining slipped forecasts.
Practise Solution Selling, don't just read about it
Reading PPVVC is not the same as running it on call 14 of the week. Practise against a Solution-Selling-tuned AI buyer with real-time coaching on which component you skipped.
Free to start. No credit card.
Practise Solution Selling live with AI
Solution Selling adoption fails for the same reason every methodology rollout fails: there is no practice gap between the Tuesday workshop and the Wednesday discovery call. Reps learn PPVVC in slides and rehearse it for the first time on a live prospect. The framework stays in the deck; the behaviour never changes.
Everboarder closes that gap with short, repeated practice against a Solution-Selling-tuned AI buyer. Diagnose Pain before the buyer volunteers it. Frame Vision in the buyer's language, not yours. Co-quantify Value under pressure. Build Consensus with a stakeholder who has a veto risk. The methodology-specific scorecard scores each component against the conversation, and real-time coaching flags the moment the rep pitches before Pain is acknowledged — while the muscle memory is still forming.
For teams, manager dashboards roll up Solution Selling adoption across the roster — which reps are certified, which components are lagging, which coaching focus should land this week. Book a demo to see it.
When to use Solution Selling vs alternative frameworks
Match the framework to the deal shape. Solution Selling is right-sized for consultative B2B where the buyer needs help defining what solved looks like.
| Framework | Use it when |
|---|---|
| Solution Selling | Consultative B2B where the buyer needs help defining what solved looks like; multi-stakeholder deals where Consensus is real work. |
| MEDDIC | $50K–$500K enterprise deals, 3–5 stakeholders, 3–9 month cycles. Qualification rigour; pairs with Solution Selling as a discovery overlay. |
| MEDDPICC | Enterprise above $100K ARR with formal procurement, security review, legal redlines, competitive RFPs. |
| BANT | Transactional inbound triage, short cycles, speed beats rigour. |
| SPIN Selling | Discovery-heavy sales where the prospect doesn't yet know they have the problem. Pairs with Solution Selling as question-design overlay. |
| SPICED | Recurring-revenue SaaS where discovery quality drives close rate; net expansion and CS integration matter as much as initial close. |
Frequently asked questions
Run Solution Selling for real
Five components are easy to read and hard to run. Get the practice and the AI buyer that turn methodology into behaviour.
Free to start. No credit card.